A single injection of Evans blue modified 177Lu-PSMA-617 provides a radiotherapeutic cure for prostate-specific membrane antigen (PSMA) tumor xenografts in mice

O Jacobson, Z Wang, G Niu, Y Ma, D Kiesewetter… - 2018 - Soc Nuclear Med
313 Objectives: Background: Prostate cancer is the most frequent malignant tumor in men
worldwide. Prostate-specific membrane antigen (PSMA), a cell-surface molecule specifically …

Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors

Z Wang, R Tian, G Niu, Y Ma, L Lang… - Bioconjugate …, 2018 - ACS Publications
Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.
Prostate-specific membrane antigen (PSMA) is a surface molecule specifically expressed by …

Establishing 177Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer

WP Fendler, AD Stuparu… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate
cancer. However, to the best of our knowledge murine models to study the biologic effects of …

[HTML][HTML] Synthesis and evaluation of [64Cu] PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer

C Cui, M Hanyu, A Hatori, Y Zhang, L Xie… - American journal of …, 2017 - ncbi.nlm.nih.gov
We radiolabeled a ligand, PSMA-617, of prostate-specific membrane antigen (PSMA) with
copper-64 (64 Cu), to evaluate the metabolism, biodistribution, and potential of [64 Cu] …

Specificity of PSMA-617 radiotherapy for prostate cancer

JA Reddy, M Nelson, LC Xu, E Westrick, M Vetzel… - Cancer Research, 2018 - AACR
Prostate-specific membrane antigen (PSMA) is a biomarker that is overexpressed on
prostate cancer as well as on the neovasculature of many non-prostate solid tumors. Lately …

177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy

SR Banerjee, V Kumar, A Lisok, J Chen, I Minn… - European journal of …, 2019 - Springer
Purpose To develop a prostate-specific membrane antigen (PSMA)-targeted
radiotherapeutic for metastatic castration-resistant prostate cancer (mCRPC) with optimized …

Tandem Isotope Therapy with 225Ac-and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer

C Meyer, A Stuparu, K Lueckerath… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising
option for metastatic castration-resistant prostate cancer. Clinical experience using 177Lu or …

[131I] MIP-1375, a small molecule prostate-specific membrane antigen (PSMA) inhibitor for targeted therapy of prostate cancer (PCa)

S Hillier, R Merkin, K Maresca, C Zimmerman, J Barrett… - 2011 - Soc Nuclear Med
361 Objectives [123 I] MIP-1072,(S)-2-(3-((S)-1-carboxy-5-(4-[123 I] iodobenzylamino)
pentyl) ureido) pentanedioic acid is a high affinity ligand for PSMA (Can Res 2009) which …

Enhanced therapeutic response to 177Lu-rhPSMA-10.1 in pre-clinical models of prostate cancer

V Vassileva, R Grønlund, B Waldron, D Gauden… - 2023 - Soc Nuclear Med
P621 Introduction: Prostate-specific membrane antigen (PSMA)-targeted radioligand
therapy has been shown to extend survival for men with metastatic prostate cancer …

Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with …

J Violet, P Jackson, J Ferdinandus… - Journal of Nuclear …, 2019 - Soc Nuclear Med
177Lu-prostate-specific membrane antigen (PSMA)–617 enables targeted delivery of β-
particle radiation to prostate cancer. We determined its radiation dosimetry and relationships …